Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate.
Curr Res Pharmacol Drug Discov
; 3: 100098, 2022.
Article
em En
| MEDLINE
| ID: mdl-35465446
ADA, adenosine deaminase; BUN, blood urea nitrogen; CG, control group; CMC-Na, sodium carboxymethyl cellulose; FEB, febuxostat; Febuxostat; GSH-PX, glutathione peroxidase; H1703, high dose of WN1703; Hyperuricemia; IL-1ß, interleukin-1ß; L1703, low dose of WN1703; M1703, median dose of WN1703; MCP, monocyte chemoattractant protein; MG, model group; Rat model; TNF-α, tumor necrosis factor-α; UA, uric acid; URAT1, urate transport protein 1; Uric acid; XOR inhibitor; XOR, xanthine oxidoreductase; YEP, yeast extract paste
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article